FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069657839> ?p ?o ?g. }

• W2069657839 endingPage "e2011045" @default.
• W2069657839 startingPage "e2011045" @default.
• W2069657839 abstract "Balanced chromosomal translocations that generate chimeric oncoproteins are considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent is the t(15;17)(q22;q21), which fuses the PML and RARA genes, giving rise to acute promyelocytic leukemia (APL). An increasing proportion of APL cases are therapy-related (t-APL), which develop following exposure to radiotherapy and/or chemotherapeutic agents that target DNA topoisomerase II (topoII), particularly mitoxantrone and epirubicin. To gain insights into molecular mechanisms underlying the formation of the t(15;17) we mapped the translocation breakpoints in a series of t-APLs, which revealed significant clustering according the nature of the drug exposure. Remarkably, in approximately half of t-APL cases arising following mitoxantrone treatment for breast carcinoma or multiple sclerosis, the chromosome 15 breakpoint fell within an 8-bp “hotspot” region in PML intron 6, which was confirmed to be a preferential site of topoII-mediated DNA cleavage induced by mitoxantrone. Chromosome 15 breakpoints falling outside the “hotspot”, and the corresponding RARA breakpoints were also shown to be functional topoII cleavage sites. The observation that particular regions of the PML and RARA loci are susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie the propensity of these agents to cause APL." @default.
• W2069657839 created "2016-06-24" @default.
• W2069657839 creator A5003372465 @default.
• W2069657839 creator A5021124944 @default.
• W2069657839 creator A5023997953 @default.
• W2069657839 creator A5041320360 @default.
• W2069657839 creator A5043076766 @default.
• W2069657839 creator A5045853218 @default.
• W2069657839 creator A5051410620 @default.
• W2069657839 creator A5079843979 @default.
• W2069657839 creator A5085154692 @default.
• W2069657839 creator A5087775526 @default.
• W2069657839 creator A5089075443 @default.
• W2069657839 date "2011-10-24" @default.
• W2069657839 modified "2023-09-27" @default.
• W2069657839 title "MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA" @default.
• W2069657839 cites W1635524817 @default.
• W2069657839 cites W1838596935 @default.
• W2069657839 cites W1898563950 @default.
• W2069657839 cites W1970018334 @default.
• W2069657839 cites W1972988800 @default.
• W2069657839 cites W1974139810 @default.
• W2069657839 cites W1982797125 @default.
• W2069657839 cites W1984183735 @default.
• W2069657839 cites W1984882433 @default.
• W2069657839 cites W1985550031 @default.
• W2069657839 cites W1991052769 @default.
• W2069657839 cites W1992842669 @default.
• W2069657839 cites W1993931486 @default.
• W2069657839 cites W1994791499 @default.
• W2069657839 cites W1998941535 @default.
• W2069657839 cites W2005557419 @default.
• W2069657839 cites W2006864755 @default.
• W2069657839 cites W2008601218 @default.
• W2069657839 cites W2009575015 @default.
• W2069657839 cites W2016132084 @default.
• W2069657839 cites W2016401533 @default.
• W2069657839 cites W2021887265 @default.
• W2069657839 cites W2022460737 @default.
• W2069657839 cites W2024236575 @default.
• W2069657839 cites W2032340333 @default.
• W2069657839 cites W2039237147 @default.
• W2069657839 cites W2044063690 @default.
• W2069657839 cites W2047991220 @default.
• W2069657839 cites W2048940082 @default.
• W2069657839 cites W2050517163 @default.
• W2069657839 cites W2051941539 @default.
• W2069657839 cites W2052246089 @default.
• W2069657839 cites W2053953221 @default.
• W2069657839 cites W2059660444 @default.
• W2069657839 cites W2064921414 @default.
• W2069657839 cites W2067578884 @default.
• W2069657839 cites W2072758446 @default.
• W2069657839 cites W2088645213 @default.
• W2069657839 cites W2092223900 @default.
• W2069657839 cites W2092302984 @default.
• W2069657839 cites W2097006389 @default.
• W2069657839 cites W2098494369 @default.
• W2069657839 cites W2105469748 @default.
• W2069657839 cites W2107579734 @default.
• W2069657839 cites W2113299316 @default.
• W2069657839 cites W2113950349 @default.
• W2069657839 cites W2120723555 @default.
• W2069657839 cites W2129291628 @default.
• W2069657839 cites W2134429215 @default.
• W2069657839 cites W2136072085 @default.
• W2069657839 cites W2137583404 @default.
• W2069657839 cites W2148305047 @default.
• W2069657839 cites W2149278033 @default.
• W2069657839 cites W2149708286 @default.
• W2069657839 cites W2151773081 @default.
• W2069657839 cites W2164304095 @default.
• W2069657839 cites W2167134612 @default.
• W2069657839 cites W2169046713 @default.
• W2069657839 cites W2172101787 @default.
• W2069657839 cites W2240786748 @default.
• W2069657839 cites W2329060102 @default.
• W2069657839 cites W2331478651 @default.
• W2069657839 cites W2290326436 @default.
• W2069657839 doi "https://doi.org/10.4084/mjhid.2011.045" @default.
• W2069657839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3219647" @default.
• W2069657839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22110895" @default.
• W2069657839 hasPublicationYear "2011" @default.
• W2069657839 type Work @default.
• W2069657839 sameAs 2069657839 @default.
• W2069657839 citedByCount "31" @default.
• W2069657839 countsByYear W20696578392012 @default.
• W2069657839 countsByYear W20696578392013 @default.
• W2069657839 countsByYear W20696578392014 @default.
• W2069657839 countsByYear W20696578392015 @default.
• W2069657839 countsByYear W20696578392016 @default.
• W2069657839 countsByYear W20696578392017 @default.
• W2069657839 countsByYear W20696578392018 @default.
• W2069657839 countsByYear W20696578392019 @default.
• W2069657839 countsByYear W20696578392020 @default.
• W2069657839 countsByYear W20696578392021 @default.
• W2069657839 countsByYear W20696578392022 @default.
• W2069657839 crossrefType "journal-article" @default.

• next